Novo Nordisk A/S (NYSE:NVO) Position Boosted by Buckingham Capital Management Inc.

Buckingham Capital Management Inc. raised its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 97.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 64,078 shares of the company's stock after acquiring an additional 31,543 shares during the period. Buckingham Capital Management Inc.'s holdings in Novo Nordisk A/S were worth $5,512,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Center for Financial Planning Inc. lifted its stake in shares of Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after purchasing an additional 123 shares in the last quarter. Daiwa Securities Group Inc. acquired a new position in shares of Novo Nordisk A/S during the third quarter worth about $28,000. Capital Performance Advisors LLP acquired a new position in shares of Novo Nordisk A/S during the third quarter worth about $42,000. Albion Financial Group UT lifted its stake in shares of Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company's stock worth $44,000 after purchasing an additional 278 shares in the last quarter. Finally, Sound Income Strategies LLC lifted its stake in shares of Novo Nordisk A/S by 82.1% during the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company's stock worth $46,000 after purchasing an additional 243 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on NVO. Cantor Fitzgerald restated an "overweight" rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. UBS Group upgraded Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research note on Monday, January 6th. StockNews.com cut Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research note on Sunday, December 29th. Finally, BNP Paribas upgraded Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, December 2nd. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $145.25.

Novo Nordisk A/S Stock Up 5.2 %

Novo Nordisk A/S stock traded up $4.33 during midday trading on Friday, hitting $88.07. The stock had a trading volume of 15,117,993 shares, compared to its average volume of 9,263,626. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The stock has a market cap of $395.19 billion, a P/E ratio of 26.77, a P/E/G ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a 12 month low of $77.82 and a 12 month high of $148.15. The business has a fifty day moving average price of $86.01 and a 200 day moving average price of $108.22.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be issued a $0.7874 dividend. This represents a yield of 1.2%. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S's dividend payout ratio is 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.